Fibrinogen composition, method and wound articles

Patent metadata

Field	Value
Publication number	US-2020038546-A1
Application number	US-201716338803-A
Country	US
Kind code	A1
Filing date	Oct 4, 2017
Priority date	Oct 5, 2016
Publication date	Feb 6, 2020
Grant date	—

Abstract

Provided is a method of forming a fibrinogen hydrogel composition, the method including providing a fibrinogen hydrogel or precursor thereof, comprising fibrinogen hydrogel forming salt. The fibrinogen hydrogel forming salt concentration is greater than or equal to the threshold concentration to form a fibrinogen hydrogel. The method further includes denaturing the fibrinogen hydrogel such as by heating. The method optionally further includes combining the fibrinogen hydrogel with a carrier material. When present, the concentration of the carrier material typically ranges from 0.1 to about 50 wt.-%. The method further includes reducing the salt concentration below the threshold concentration to form a fibrinogen hydrogel.

First claim

1 - 56 . (canceled)

57 . A method of forming a fibrinogen hydrogel composition comprising:
providing a fibrinogen hydrogel or precursor thereof, comprising fibrinogen hydrogel forming salt at a concentration greater than or equal to the threshold concentration to form the fibrinogen hydrogel; denaturing the fibrinogen hydrogel; reducing the salt concentration below the threshold concentration to form the fibrinogen hydrogel before and/or after optionally combining the fibrinogen hydrogel with the carrier material.

58 . The method of claim 57 , wherein the fibrinogen hydrogel precursor comprises an aqueous solution comprising fibrinogen and the fibrinogen hydrogel forming salt.

59 . The method of claim 57 , wherein the fibrinogen hydrogel forming salt comprises sodium citrate optionally in combination with sodium chloride.

60 . The method of claim 57 , wherein the threshold hydrogel forming salt concentration of the aqueous solution is at least 0.45 wt.-%.

61 . The method of claim 57 , wherein the fibrinogen hydrogel composition further comprises a fibrinogen hydrogel plasticizer.

62 . The method of claim 61 wherein the plasticizer comprises a sugar alcohol, an alkane diol, or a combination thereof.

63 . The method of claim 57 , further comprising forming the fibrinogen hydrogel composition into a sheet, foam, or a plurality of pieces.

64 . The method of claim 57 , wherein the step of reducing the fibrinogen hydrogel forming salt concentration comprising rinsing the hydrogel with an aqueous solution.

65 . The method of claim 57 , further comprising dehydrating the fibrinogen hydrogel composition.

66 . The method of claim 57 , wherein the denaturing is accomplished by heating.

67 . The method of claim 65 , wherein the dehydrated denatured fibrinogen hydrogel composition has a salt concentration no greater than 20 wt.-%.

68 . The method of claim 57 , further comprising forming the fibrinogen hydrogel composition into a plurality of pieces.

69 . The method of claim 57 , further comprising combining the fibrinogen hydrogel with 0.1 to about 50 wt.-% of a carrier material.

70 . The method of claim 69 , wherein the carrier material comprises a water soluble polymer having a Fikentscher K-value of at least K-90.

71 . The method of claim 69 , wherein the carrier material comprises a polymer.

72 . The method of claim 71 , wherein the polymer comprises polymerized units of N-vinyl lactam polymer.

73 . The method of claim 69 , wherein the carrier material further comprises a swelling agent.

74 . The method of claim 73 , wherein the swelling agent also functions as a plasticizer for the fibrinogen hydrogel.

Assignees

• 3M Innovative Properties Co

Inventors

• Dizio James P
• Tian Zhicheng
• Bjork Jason W
• Determan Amy S
• Asmus Robert A
• O'Hare Jonathan J

Classifications

• A61L24/106

  Fibrin; Fibrinogen · CPC title

• A61L2300/418

  Agents promoting blood coagulation, blood-clotting agents, embolising agents · CPC title

• A61L26/008

  Hydrogels or hydrocolloids · CPC title

• A61L15/32

  Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin {(A61L15/225 takes precedence)} · CPC title

• A61L26/0042 Primary

  Fibrin; Fibrinogen · CPC title